In a phase 2 trial of early symptomatic Alzheimer disease (259 with low–medium tau analysed), ceperognastat 0.75 mg or 3 mg did not slow iADRS decline vs placebo at 100 weeks; 3 mg showed 32% greater progression and more serious adverse events (26.4% vs 15.7%).
RCTn = 327
Fleisher et al. Ceperognastat in Early Symptomatic Alzheimer Disease: A Randomized Clinical Trial